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ABSTRACT
Background: MicroRNAs (miRs) are small RNA molecules, influencing messenger 
RNA (mRNA) expression and translation, and are readily detectable in blood. Some 
have been reported as potential breast cancer biomarkers. This study aimed to identify 
and validate miRs indicative of breast cancer.
Results: Based on the discovery and literature, 18 potentially informative 
miRs were quantified in the validation cohort. Irrespective of patient and tumour 
characteristics, hsa-miR-652-5p was significantly upregulated in the malignant 
compared to benign patients (1.26 fold, P = 0.005) and therefore validated as potential 
biomarker. In the validation cohort literature-based hsa-let-7b levels were higher in 
malignant patients as well (1.53 fold, P = 0.011). Two miRs differentiated benign 
wildtype from benign BRCA1 mutation carriers and an additional 8 miRs differentiated 
metastastic (n = 8) from non-metastatic (n = 41) cases in the validation cohort.
Methods: Pre-treatment plasma samples were collected of patients with benign 
breast disease and breast cancer and divided over a discovery (n = 31) and validation 
(n = 84) cohort. From the discovery cohort miRs differentially expressed between 
benign and malignant cases were identified using a 2,000-miR microarray. Literature-
based miRs differentiating benign from malignant disease were added. Using RT-qPCR, 
their expression was investigated in a validation cohort consisting of pre-treatment 
benign, malignant and metastatic samples. Additionally, benign and malignant cases 
were compared to benign and malignant cases of BRCA1-mutation carriers.
Conclusions: Plasma microRNA levels differed between patients with and without 
breast cancer, between benign disease from wildtype and BRCA1-mutation carriers 
and between breast cancer with and without metastases. Hsa-miR-652-5p was 
validated as a potential biomarker for breast cancer.
www.oncotarget.com                               Oncotarget, 2018, Vol. 9, (No. 36), pp: 24335-24346
INTRODUCTION
Early diagnosis improves breast cancer survival [1]. 
National screening programs aim to detect breast cancer at 
an early stage. Woman aged 50–75 are invited for biennial 
screening with additional annual screening programs for 
patients with a cumulative life time risk of breast cancer of 
over 20% (40–50 years) and BRCA1/2-mutation carriers 
(25–75 years). Mammography and breast MRI (BRCA1/2-
mutation carriers) are the radiological modalities used in 
these programs. Mammographic sensitivity is, however, 
generally impaired in patients with dense breast tissue 
found especially in the younger population [2]. In the 
national screening program performed in the general 
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population 20% of the carcinomas is detected between two 
screening moments [3]. Improved sensitivity of screening 
could possibly reduce the number of these interval 
carcinomas. Improved specificity could diminish distress 
as a result of false-positive (mammographic) result. 
Biomarkers detectable in body fluids could be valuable as 
this allows for minimally invasive screening and repetitive 
monitoring [4].
Blood-based microRNAs (miRs) are potential 
biomarkers for breast cancer. MiRs are small RNA 
molecules that influence regular messenger RNA (mRNA) 
expression and translation by binding with (partially) 
complementary sequences on target mRNAs aided by 
the RNA-induced slicing complex [5]. The resulting 
post-transcriptional gene modulation can lead to mRNA 
degradation, translational inhibition or translational 
activation [6]. MiRs, as opposed to mRNAs, are extremely 
stable under different conditions and readily detectable in 
serum and plasma [7].
In breast cancer, multiple miRs have been associated 
with oncogenic driver events, cancer invasiveness, adverse 
clinical outcome and therapy resistance [5, 8–12]. Most 
of these studies used tissue samples whereas blood-based 
markers are needed for screening purposes. Previous 
studies focusing on miRs present in the circulation (serum 
or plasma) showed that the quantity and composition of 
blood-based miRs can predict the presence of tumour 
[7, 9, 13, 14]. Differences in miR expression levels 
between breast cancer patients and healthy controls enables 
the use of miRs as a blood-based diagnostic biomarker.
This study aimed to identify and validate miRs 
indicative for breast cancer in plasma of patients prior 
to surgery who did not receive neo-adjuvant treatment 
with a long follow-up term. The cohort consisted of 
patients without and with a family history of breast cancer 
including BRCA1-mutation carriers. MiRs discriminative 
for benign and malignant breast disease in a discovery 
cohort and miRs reported in literature to be differentially 
expressed between breast cancer patients and healthy 
controls [15–21] were validated in an independent 
validation cohort. 
RESULTS
One discovery sample (3.3%) was excluded based 
on a high haemolysis score resulting in 29 suitable 
samples. In the validation cohort 4/84 (4.7%) and 1/84 
(1.2%) samples were excluded based on a too low 
expression level of the 5 reference miRs and/or a high 
haemolysis score, respectively, resulting in 79 suitable 
samples. Baseline characteristics are specified in Table 
1. The two cohorts were well balanced considering the 
clinical parameters. The median follow-up time was 
shorter in the discovery cohort than the validation cohort: 
9.2 [interquartile range (IQR) 7.7.-10.1] versus 11.0 [IQR 
7.4-11.8] years, P = 0.043. Breast cancer metastases 
occurred in 6 (32%) and 8 (16%) of the breast cancer 
patients during follow-up with a median time since blood 
sampling of 0.9 [IQR 0.3-4.4] and 2.1 [IQR 0.3-4.4] years 
for the discovery and validation cohort, respectively, P = 
0.53. Local breast cancer recurrence was not reported in 
either cohort during follow-up.
Discovery phase
The unsupervised analysis of the 756 miRs 
detected with the microarray clearly showed a separated 
hierarchical clustering of the benign wildtype BRCA1 and 
the other benign samples (Figure 1). The benign BRCA1-
mutations carrier samples, however, clustered with the 
malignant cases.
Of the 756 miRs, 7 miRs were significantly 
differentially expressed between benign and malignant 
pooled samples and were therefore selected for validation 
(Supplementary Table 1). Since the benign BRCA1-
mutations carriers samples, clustered with the malignant 
cases, 4 additional miRs most discriminatory between 
benign BRCA1-mutation carriers and wildtype samples 
were added to our selection to further investigate this 
observation (Figure 2 and Supplementary Table 1). 
In addition, 11 literature-based miRNA and 6 stable 
expressed reference miRs selected from the microarray 
were included for analysis in the validation cohort 
(Supplementary Table 2). Twenty-five out of 30 miRs 
(5 reference miRs for quantification, 2 haemolysis markers 
and 18 candidate miRs) passed our quality control steps 
with respect to reproducibility and PCR efficiency 
(Figure 2). The 18 candidate miRs were quantified in the 
validation samples by RT-qPCR using validated Taqman 
mature MicroRNA Assays (ThermoScientific).
Validation phase
Benign versus malignant
Hsa-miR-652-5p, a selected candidate-miR in the 
discovery cohort, was significantly upregulated in the 
validation cohort and therefore validated as a potential 
biomarker for the detection of breast cancer. Has-miR-
652-5p was statistically significant upregulated in the 
malignant samples (n = 49) compared to the benign 
samples (n = 30), fold change 1.26 (P = 0.006) (Table 
2 and Figure 3). Hsa-let-7b, a literature-based miR, also 
was statistically significant upregulated in malignant 
samples compared to benign samples, fold change 1.53 
(P = 0.011) (Table 2 and Figure 3). Neither hsa-miR-
652-5p nor hsa-let-7b showed a significant correlation 
with age (Spearman’s’ rank correlation coefficient -0.044 
(P = 0.77) and 0.169 (P = 0.257), respectively). Within 
the n = 49 breast cancer cases, no statistical differences in 
the expression levels of both miRs were found regarding 
tumour stage, nodal status, hormonal receptor status, 
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Table 1: Clinical characteristics for the discovery and validation group 
All 
Discovery Validation
P-value
(n = 29) (n = 79)
Age median in years (min-max) ¥ 49.9 (39.7–55.2) 55.3 (48.9–61.5) 0.07
Follow up median in years (min-max)¥ 9.2 (7.7–10.1) 11.0 (7.4–11.8) 0.043
Classification all samples^ 0.37
Benign 10 (34%) 30 (38%)
Non-metastatic BC 13 (45%) 41 (52%)
Metastatic BC 6 (21%) 8 (10%)
Classification BRCA1-mutation carriers (n = 5) (n = 3)
Benign 3 1
Non-metastatic BC 1 2
Metastatic BC 1 0
Classification familial breast cancer^^ (n = 6) (n = 20)
Benign 0 8 (40%)
Non-metastatic BC 4 (67%) 10 (50%)
Metastatic BC 2 (33%) 2 (10%)
Breast cancer patients (n = 19) (n = 49)
Tumour stage^^ 0.26
T1 9 (47%) 28 (57%)
T2 7 (37%) 19 (39%)
T3 3 (16%) 2 (4%)
Nodal stage^^ 0.12
N0 5 (26%) 25 (51%)
N1 10 (53%) 16 (33%)
N2 3 (16%) 4 (8%)
N3 0 4 (8%)
Unknown 1 (5%) 0
Oestrogen receptor status^ 0.51
Negative 5 (26%) 9 (18%)
Positive 14 (74%) 40 (82%)
Her2Neu receptor status^^ 0.73
Negative 17 (89%) 33 (67%)
Positive 2 (11%) 9 (18%)
Unknown 0 7 (14%)
Triple negative breast cancer* ^^ 0.22
No 14 (74%) 43 (88%)
Yes 5 (26%) 5 (10%)
Unknown 0 1 (2%)
BC - Breast Cancer. ¥ Mann–Whitney U test ^Fishers exact test with a Freeman-Halton extension when appropriate (2-tailed 
P-value). ^^Kruskall Wallis test. *ER-receptor, PR-receptor and Her2Neu receptor negative breast cancer.
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HER2 status or triple negative breast cancer (TNBC) 
status (data not shown).
BRCA1-mutation carriers 
The 4 miRs selected in the discovery cohort based 
on a 2-fold higher expression in the benign BRCA1-
mutation carriers versus wildtype benign cases showed no 
differential expression in the validation cohort (data not 
shown). When investigating expression in the individual 
benign samples (discovery and validation cohort) of 
BRCA1-mutation carriers (due to the low numbers, 
discovery and validation cohort combined) with wildtype 
benign samples (validation cohort) both hsa-miR-185-5p 
and hsa-miR-675-5p showed an differential expression 
with a fold change 2.16 (P = 0.005) and 0.25 (P = 
<0.001), respectively (Table 3). No differences were found 
comparing malignant BRCA1-mutation carriers (discovery 
and validation cohort, n = 3) to wildtype malignant 
samples (validation cohort, n = 39) (data not shown).
Malignant; non-metastatic versus metastatic 
breast cancer
Eight out of 49 (16.3%) breast cancer patients were 
diagnosed with metastatic breast cancer during follow-up 
(Table 1). Comparing metastatic to non-metastatic breast 
cancer samples hsa-miR-135a, hsa-miR-195-5p and hsa-
miR-675-5p showed an upregulated expression whereas 
hsa-miR-18b-5p, hsa-miR-21-5p, hsa-miR-29b, hsa-miR-
202-3p and hsa-miR-382-3p showed a downregulated 
expression in metastatic samples (Table 2 and Figure 4).
DISCUSSION
MiRs can be useful biomarkers and we identified 
one, hsa-miR-652-5p, for which pre-treatment plasma 
levels are different between malignant and non-malignant 
disease. The higher expression of this miR in breast cancer 
patients was confirmed in an independent validation 
cohort. As the expression did not correlate with either 
patients’ age, tumour stage, nodal stage or hormonal 
receptor status and Her-2/Neu status, hsa-miR-652-5p may 
be widely applicable as a possible blood-based biomarker 
for breast cancer detection. The use of a miR signature 
is, however, preferred over the use of a single miR as a 
potential biomarker since a combination of miRs usually 
improves diagnostic accuracy [17, 25, 26]. In the current 
cohort only miR hsa-miR-652-5p was validated as a 
potential biomarker. In line with these results, hsa-miR-652 
has previously been reported as a breast cancer biomarker 
with a upregulated expression comparing benign breast 
diseases to breast cancer patients [26] and healthy controls 
versus benign and versus malignant breast diseases [27]. 
As in our cohort, both previously published studies showed 
an upregulated expression irrespective of tumour stage, 
Figure 1: Dendrogram unsupervised hierarchical clustering discovery cohort. Clustering of the 12 groups present in the 
discovery cohort, based on the expression of n = 756 expressed miRs, was performed with the software package of GenEx v.4.1.76.1 from 
MultiD. Clustering method: Ward’s Algorithm. Distance measure as indicated above the dendogram: Euclidean. *Groups which contain 
BRCA1 mutation carriers.
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thus supporting the use of hsa-miR-652 as a potential 
biomarker for early stage breast cancer detection. To the 
best of our knowledge the genome context or target context 
of hsa-miR-652-5p has not been described previously.
The literature based candidate hsa-let-7b was also 
significantly differentially expressed between benign 
and malignant samples within the validation cohort. 
The let-7-family is associated with multiple oncogenes 
and upregulated let-7-levels have been associated with 
a poor prognosis and poor overall survival [20, 28]. 
The upregulation observed is in line with other studies 
showing an upregulated expression in breast cancer 
patients [17, 28, 29] with higher levels in metastatic 
breast cancer [29]. Higher levels of hsa-let-7b between 
metastatic and non-metastatic patients were, however, 
not observed in the current cohort. The validation 
cohort, however, did show 8 miRs that were significantly 
different in breast cancer patients with metastasis 
Figure 2: Discovery phase flow-chart. §Supplementary Table 2 displays a detailed description of the pooled groups. *Mann-Whitney U 
test. QC = Quality control. ¶Too high expressed in multiplex vs uniplex; appears to detect additional transcripts. ¥Poor amplification and too 
low expressed for a reliable analysis. ±Too low expressed for a reliable analysis. **Poor amplification curves and poor efficiency in multiplex.
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Table 2: Differentially expressed (relative expression) validation cohort 
Clinical group
All Malignant
malignant (49) vs Benign (30) Metastatic (8) vs Non-metastatic (41) 
miR Fold change1 P-value* P-value** Fold change2 P-value* P-value**
hsa-miR-18b-5p 0.91 >0.05 >0.05 0.52 0.028 0.014
hsa-miR-21-5p 0.96 >0.05 >0.05 0.50 0.022 0.014
hsa-miR-29b 1.06 >0.05 >0.05 0.71 0.044 0.022
hsa-miR-135-3p 0.80 >0.05 >0.05 1.89 0.017 0.008
hsa-miR-195-5p 1.06 >0.05 >0.05 1.02 0.040 0.019
hsa-miR-202-3p 1.11 >0.05 >0.05 0.48 0.033 0.017
hsa-miR-382-3p 0.72 >0.05 >0.05 0.09 0.011 0.006
hsa-miR-652-5p 1.26 0.006 >0.05 0.99 >0.05 >0.05
hsa-miR-675-5p 1.41 >0.05 >0.05 1.36 0.006 0.003
hsa-let7b 1.53 0.011 >0.05 0.91 >0.05 0.031
1Fold change (malignant/benign). 2Fold change (metastatic/non-metastatic). 
*Comparison between groups using the Mann–Whitney U test. *P-value based on correction by Benjamini-Hochberg method 
(10% FDR). **P-value based on correction by Benjamini-Hochberg method (5% FDR).
Figure 3: Relative miR expression of candidate miRs for malignant versus benign validation samples. The y-axis reflects 
the relative miR expression as compared to the overall expression of the 18 miRs evaluated in the validation cohort. The median and 
interquartile ranges per miR are displayed by the box-plot. *P-value< 0.05 (Mann–Whitney U test, after correction by Benjamini-Hochberg 
method (10% FDR).
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compared to those without. These miRs could possibly 
be used to predict the onset of breast cancer metastasis. 
Although some of these miRs have been described as 
possible biomarkers differentiating between healthy 
and malignant samples [15, 18, 19, 30, 31], only the 
downregulation of hsa-miR-29b has previously been 
reported to differentiate non-metastatic from metastatic 
breast cancer samples [31]. When performing an 
additional sensitivity analysis comparing the individual 
non-metastatic (n = 13) to metastatic samples (n = 6) 
of the discovery cohort no significant differences were 
found in miR expression levels. This can possibly be 
explained by the limited patient number available in the 
discovery cohort and overall small differences in absolute 
miR expression levels found in both cohorts. Therefore, 
independent validation of these miRNAs in a large cohort 
is needed.
Although promising as potential biomarkers, several 
methodological issues have to be resolved to take miR 
expression data to the clinical arena. Multiple techniques 
Figure 4: Relative miR expression of candidate miRs for metastatic versus non-metastatic validation samples. The 
y-axis reflects the relative miR expression as compared to the overall expression of the 18 miRs evaluated in the validation cohort. 
The median and interquartile ranges per miR are displayed by the box-plot. *P-value< 0.05 (Mann–Whitney U test, after correction by 
Benjamini-Hochberg method (10% FDR). 
Table 3: miR expression for BRCA1 vs non-BRCA1 samples 
Clinical group Benign
BRCA1 benign (4) vs Non-BRCA1 benign (29)
miR Fold change P-value* P-value**
hsa-miR-185-5p 2.16 0.005 >0.05
hsa-miR-675-5p 0.25 <0.0001 0.003
Fold change (wildtype/BRCA1 mutation carriers).
*Comparison between groups using the Mann–Whitney U test. *P-value based on correction by Benjamini-Hochberg 
method (10% FDR). **P-value based on correction by Benjamini-Hochberg method (5% FDR).
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are described for miR detection and selection or the type 
of normalisation of miR-data, possibly influencing the 
results or interpretation. The range of the miR expression 
level is influenced by the normalisation on which a relative 
expression or fold change is calculated. The normalisation 
of the expression levels varies between studies potentially 
hampering validation of previously obtained results. In the 
search for a potential breast cancer biomarker differences 
in clinical characteristics influencing miR expression 
levels should be accounted for when comparing cohorts. 
As shown in multicentre cohorts harbouring breast cancer 
patients, differences in MIR expression are also present 
between patients with benign breast disease(s) and healthy 
controls [25, 26]. In a large cohort, Shimomura et al. 
underlined the wide variation in miR expression levels 
present within the healthy population [25].
The strength of the current study is the use of a 
validation phase after an initial discovery phase. The 
cohorts investigated reflect a general population but 
included also women with a high familial risk of breast 
cancer and BRCA1-mutation carriers (4 benign and 4 
malignant samples). The use of pre-treatment breast 
cancer samples enabled a comparison of miR expression 
levels without a possible influence of (systemic) therapy.
Limitations of the current study may include the 
pooled sample-design of the discovery phase. This could 
have limited the identification of candidate miRs for use 
in the validation phase. Furthermore, subgroups analyses 
in the validation cohort were performed with a limited 
patient number. The relative low expression of hsa-
miR-652-5p as compared to other miRs (–0.25) in the 
validation cohort limits the use of the miR as a potential 
biomarker due to an increased risk of measurements 
errors influencing the diagnostic accuracy. Given that 
only hsa-miR-652-5p showed an differential expression in 
both cohorts the diagnostic accuracy for this single miR 
was not evaluated.
Unexpectedly, when evaluating the results of the 
unsupervised hierarchical clustering in the discovery 
phase, benign samples of BRCA1-mutation carriers 
clustered with the malignant samples. A differential 
expression for two other miRs (hsa-miR-185-5p and hsa-
miR-675-5p) was additionally found when comparing 
BRCA1 mutant versus wildtype cases. These results 
and the differential expression as found by Erturk and 
colleagues [32, 33] emphasize the need for validation 
of miR biomarkers as a screening tool in well-balanced 
cohorts including BRCA1-mutation carriers, especially 
since in the general population individuals may be 
unaware of their BRCA-mutation status. This underlines 
the need for well-balanced cohorts. In this field of 
research it is of utmost importance that expression data is 
confirmed in other cohorts before these miRs are used to 
guide screening and treatment. Furthermore, differences in 
measurement techniques and normalization methodologies 
should be minimized enabling an adequate comparison 
and thus meaningful validation. 
METHODS
Patients
After informed consent, pre-treatment blood 
samples were obtained of patients with benign breast 
disease and those with breast cancer at Erasmus MC, the 
university hospital in Rotterdam, the Netherlands. This 
study was approved by the institutional review board 
(Medical Ethical committee number; MEC-2005-002). 
Following inclusion 114 samples were separated over 
the discovery cohort (n = 30) and the validation cohort 
(n = 84) dividing the benign and malignant cases. At time 
of blood sampling patients were allocated to the benign 
or malignant group. Patients were included only if the 
diagnosis was histologically proven (if applicable) and long-
term follow-up was available. Sufficient plasma (more than 
500 µL) had to be available. Patients with a previous history 
of invasive carcinoma, patients for whom less plasma 
was available and breast cancer patients with metastasis 
at time of diagnoses were excluded. Male patients were 
excluded. Patients who were allocated to the benign group 
but turned out to have malignant disease during follow-up 
were additionally excluded in this study. Survival status and 
recurrence status was updated regularly using patients’ files. 
Last follow-up date was June 13th 2017.
Samples 
Blood was obtained at the outpatient laboratory of 
the Erasmus MC. Following venous blood withdrawal 
(4 tubes per patients), samples were directly divided over 
micronics tubes (1 mL) separating whole blood, serum 
and plasma and stored in the freezer (–80° C). Prior to 
defrosting, dithiothreitol (DTT 5 mM final) was added to 
the plasma to prevent degradation of nucleic acids during 
defrosting and handling. Total RNA was isolated from 
200 uL plasma with the Norgen Total RNA Purification 
Kit as recommended by the manufacturer (Norgen Biotek 
Corp., Canada), adjusted to 43% ethanol during isolation 
to optimize the miRNA recovery yield.
For the discovery phase, 12 samples were prepared, 
each sample containing a pool of 2 to 3 plasma RNA 
aliquots of patients with similar clinical characteristics 
(Supplementary Table 3). For the validation phase, only 
individual samples were used.
To ensure that good quality RNA was used only, 
all RNA samples were checked according to two sample 
quality control steps. First, 3 uL (5%) of the isolated total 
RNA was used in a multiplex RT-qPCR pre-screen with 8 
validated Taqman MicroRNA Assays (ThermoScientific, 
The Netherlands). The median value of 5 stable-expressed 
reference miRs (Figure 2 and Supplementary Table 4) 
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included in this 8-miR pre-screen panel served as a 
reference value by applying a cut-off value of 20 qPCR 
cycles. Second, haemolysis miR (Figure 2) expression 
was evaluated. The ratio of miR-451 over miR-23a was 
used to evaluate the possible presence of haemolysis in 
the samples as described previously [22]. As we had the 
median of 25 miRs (Figure 2) available quantified by 
RT-qPCR, we decided to use the more robust 25 miR 
median normalized miR-451 levels in the final analysis. 
Samples were excluded from the final analysis if a median 
normalized miR-451 value > 6.0 was measured. 
Discovery phase
miR profiling
Pooled discovery samples containing either 400 or 
600 µL plasma were shipped to TATAA (TATAA BioCenter, 
Sweden) for 3D-Gene miRNA profiling (Toray Industries, 
Japan). The 3D-Gene DNA chips contain 2,000 human 
miRNAs selected from database mirBase release 19.0. The 
chips were processed according to the standard protocol of 
the manufacturer (http://www.3d-gene.com/en/).
Data processing
Analysing the microarray data, the presence or 
absence of a signal was calculated as follows: spots 
with intensities higher than the background average + 
2-standard deviations were considered “present”. The 
background average was subtracted from the signal 
intensities to give the background subtracted values, 
after which the median signal intensity was calculated. 
Finally, a normalisation factor was calculated as: 25 
divided by the median signal intensity of all background-
subtracted data, after which the background subtracted 
data were multiplied by this normalisation factor. Next, 
only miRs that were detectable in at least 20% of the 
groups (Supplementary Table 3) and for which validated 
Taqman assays were expected to be available [miR-
1 to miR-700] were selected for further analysis in the 
unsupervised analysis (Supplementary Table 4). GeNorm 
and NormFinder, both present in the software package 
of GenEx v.6.1 from MultiD, were used to identify the 
most stable expressed miRs to uniformly normalise the 
microarray and Taqman reverse transcriptase polymerase 
chain reaction (RT-qPCR) data. For the microarray data, 
after background subtraction, thus identified 5 reference 
miRs (Figure 2) were used for normalizing the RT-qPCR 
data before identifying the differentially expressed miRs. 
Apart from the miR expression present in the 
unsupervised analysis, 11 additional literature-based miRs 
(Figure 2 and Supplementary Table 3) previously reported 
to differentiate benign from malignant breast disease were 
selected [15–20].
Validation phase 
miR profiling
Twenty-five miRs (20 selected miRs and 5 
reference miRs) were quantified in the validation cohort 
by RT-qPCR using validated Taqman mature MicroRNA 
Assays (ThermoScientific) (Supplementary Table 4). To 
enable accurate and reliable quantification of multiple 
miRs in small RNA samples, an extended multiplex RT 
reaction (40 cycles) was performed as described by the 
manufacturer for their custom Taqman Array MicroRNA 
fluidic cards. This was followed by 15 PCR rounds of pre-
amplification (PreAmp mastermix from ThermoScientific) 
and 40 rounds of PCR for quantification [14]. The 
performance of the RT-qPCR assays was checked using 
a serially diluted human breast cancer cell line control 
sample. The control consisted of total RNA isolated 
from different breast cancer cell lines to ensure all miRs 
were present in this control sample. A second check was 
performed with a cell line control sample containing total 
RNA from the same cell lines, this time however isolated 
from FFPE to evaluate the performance of the assays with 
degraded RNA. Only Taqman miRNA assays that could 
amplify miR targets homogeneously in a multiplexed 
reverse transcriptase setting within both serially diluted 
control samples were used for sample validation. This was 
defined as a specific, with 90-110% efficiency measured, 
linearly amplified end product [23].
Data processing
The median of all 25 miRs selected showed the 
lowest M-value and smallest inter- and intragroup 
variation and was therefore used as reference value 
to normalise RT-qPCR data in the validation phase 
(Supplementary Table 4).
MiR expression levels were compared in the 
validation cohort between 1) benign versus malignant 
samples and 2) non-metastatic versus metastatic 
breast cancer samples. Secondly the expression of the 
differentially expressed miRs were evaluated according 
to patients’ age (≤50 versus >50), familial breast cancer 
(no versus yes), tumour stage (T1 versus >T1), nodal 
stage (N0 versus N+), hormone receptor status, Her2Neu 
receptor status and triple negative status (negative for 
ER, PR and Her2Neu). Hormonal receptor status was 
considered positive in case of ≥10% nuclear staining 
of the oestrogen receptor and/or progesterone receptor. 
Based on the unsupervised clustering of miRs in the 
discovery cohort, separate analyses were performed with 
the BRCA1-mutation carrier samples (due to low numbers, 
combined from both the discovery and validation phase). 
Benign and malignant samples from BRCA1 carriers were 
compared to respectively wildtype benign and malignant 
samples of the validation cohort.
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Statistics
All data were analysed with SPSS version 21 (IBM). 
To compare groups with numerical variables, the Mann–
Whitney U test was used. The Fisher’s exact test was used 
to compare groups in 2×2 contingency tables. For 2×3 and 
2×4 tables, the Freeman-Halton extension of the Fisher’s 
exact probability test was used. To correct for multiple 
comparisons P-values were adjusted for type I errors by 
using the Benjamini-Hochberg false discovery rate (FDR) 
method at a cut off of 10% [24]. All P-values are 2-sided 
and P < 0.05 was considered statistically significant. 
CONCLUSIONS
With hsa-miR-652-5p showing promising results 
as a potential early breast cancer biomarker and multiple 
studies showing discriminative blood-born miR expression 
for the detection of breast cancer, future research should 
focus on validating previously detected miRs and 
preferably miR-signatures in cohorts representative of 
the screening population. This could lead to sufficient 
validation of a miR-signature serving as biomarker and 
thereby enabling improved early breast cancer as well as 
early metastasis detection. 
Abbreviations
FDR: False-Discovery Rate; FFPE: Formalin-
Fixed Paraffin-Embedded; HER2: Human Epidermal 
growth factor Receptor 2; IQR: Interquartile Range; MIR: 
MicroRNA; MRNA: Messenger RNA; PCR: Polymerase 
Chain Reaction; RT-qPCR: Quantative Reverse Tran-
scription PCR; TNBC: Triple Negative Breast Cancer. 
Author contributions 
The authors ML, SS, AS, MT, LK, and JM designed 
the study. Author MT included the patients and ML and 
SS gathered the patient data. Author ML, SS and AS 
drafted the manuscript. Measurements were performed by 
VW, RR-M and AS. Author MS performed the statistical 
analysis. All authors critically revised the manuscript for 
intellectual content. Author AS is guarantor of the study.
ACKNOWLEDGMENTS
The authors would like to thank the foundations: 
Stichting Physico Therapeutisch Instituut, ‘A Sister’s 
Hope’ and ‘Boezemvriendinnen’ for their financial support 
and their given trust in the research project.
CONFLICTS OF INTEREST
All authors declare to have no potential or actual 
conflicts of interest regarding the manuscript submitted. 
FUNDING SUPPORT
The study was financially supported by the 
foundations: Stichting Physico Therapeutisch Instituut, 
‘A Sister’s Hope’ and ‘Boezemvriendinnen’. Author AMS 
was funded through the cancer genomics Netherlands grant 
from the Netherlands organization of Scientific research 
(NWO). Funding was to finance the materials used to 
perform the analysis within the laboratory. No funding was 
used for generating the research question and study design, 
interpretation of the data or the writing of the manuscript.
REFERENCES
 1. Saadatmand S, Bretveld R, Siesling S, Tilanus-Linthorst 
MM. Influence of tumour stage at breast cancer detection 
on survival in modern times: population based study in 173 
797 patients. BMJ. 2015; 351:h4901.
 2. Boyd NF, Guo H, Martin LJ, Sun L, Stone J, Fishell E, 
Jong RA, Hislop G, Chiarelli A, Minkin S, Yaffe MJ. 
Mammographic density and the risk and detection of breast 
cancer. N Engl J Med. 2007; 356:227–236.
 3. Fracheboud J. vLPA, Sankatsing VDV, Ripping TM, 
Broeders MJM, van Ineveld BM, Heijnsdijk EAM, Verbeek 
ALM, Holland R, den Heeten GJ, de Bruijn A.E, de Koning 
HJ. National evaluation of breast cancer screening in the 
Netherlands 1990-2011/2012. http://wwwerasmusmcnl/
public-health/publications-collaborations/reports/
evaluatie-borstkanker/pdf/. 
 4. Liang W, Lawrence WF, Burnett CB, Hwang YT, Freedman 
M, Trock BJ, Mandelblatt JS, Lippman ME. Acceptability 
of diagnostic tests for breast cancer. Breast Cancer Res 
Treat. 2003; 79:199–206.
 5. Iorio MV, Casalini P, Tagliabue E, Menard S, Croce CM. 
MicroRNA profiling as a tool to understand prognosis, 
therapy response and resistance in breast cancer. Eur J 
Cancer. 2008; 44:2753–2759.
 6. Vasudevan S, Tong Y, Steitz JA. Switching from repression 
to activation: microRNAs can up-regulate translation. 
Science. 2007; 318:1931–1934.
 7. Mostert B, Sieuwerts AM, Martens JW, Sleijfer S. 
Diagnostic applications of cell-free and circulating tumor 
cell-associated miRNAs in cancer patients. Expert Rev Mol 
Diagn. 2011; 11:259–275.
 8. van Schooneveld E, Wouters MC, Van der Auwera I, Peeters 
DJ, Wildiers H, Van Dam PA, Vergote I, Vermeulen PB, 
Dirix LY, Van Laere SJ. Expression profiling of cancerous 
and normal breast tissues identifies microRNAs that 
are differentially expressed in serum from patients with 
Oncotarget24345www.oncotarget.com
(metastatic) breast cancer and healthy volunteers. Breast 
Cancer Res. 2012; 14:R34.
 9. Zhu W, Qin W, Atasoy U, Sauter ER. Circulating 
microRNAs in breast cancer and healthy subjects. BMC 
Res Notes. 2009; 2:89.
10. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, 
Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M, 
Menard S, Palazzo JP, Rosenberg A, et al. MicroRNA gene 
expression deregulation in human breast cancer. Cancer 
Res. 2005; 65:7065–7070.
11. Rodriguez-Gonzalez FG, Sieuwerts AM, Smid M, Look 
MP, Meijer-van Gelder ME, de Weerd V, Sleijfer S, 
Martens JW, Foekens JA. MicroRNA-30c expression level 
is an independent predictor of clinical benefit of endocrine 
therapy in advanced estrogen receptor positive breast 
cancer. Breast Cancer Res Treat. 2011; 127:43–51.
12. Foekens JA, Sieuwerts AM, Smid M, Look MP, de Weerd 
V, Boersma AW, Klijn JG, Wiemer EA, Martens JW. Four 
miRNAs associated with aggressiveness of lymph node-
negative, estrogen receptor-positive human breast cancer. 
Proc Natl Acad Sci U S A. 2008; 105:13021–13026.
13. Shao Y, Geng Y, Gu W, Huang J, Pei H, Jiang J. Prognostic 
role of tissue and circulating microRNA-200c in malignant 
tumors: a systematic review and meta-analysis. Cell Physiol 
Biochem. 2015; 35:1188–1200.
14. Sieuwerts AM, Mostert B, Bolt-de Vries J, Peeters D, 
de Jongh FE, Stouthard JM, Dirix LY, van Dam PA, Van 
Galen A, de Weerd V, Kraan J, van der Spoel P, Ramirez-
Moreno R, et al. mRNA and microRNA expression 
profiles in circulating tumor cells and primary tumors of 
metastatic breast cancer patients. Clin Cancer Res. 2011; 
17:3600–3618.
15. Si H, Sun X, Chen Y, Cao Y, Chen S, Wang H, Hu C. 
Circulating microRNA-92a and microRNA-21 as novel 
minimally invasive biomarkers for primary breast cancer. 
J Cancer Res Clin Oncol. 2013; 139:223–229.
16. Kleivi Sahlberg K, Bottai G, Naume B, Burwinkel B, Calin 
GA, Borresen-Dale AL, Santarpia L. A serum microRNA 
signature predicts tumor relapse and survival in triple-
negative breast cancer patients. Clin Cancer Res. 2015; 
21:1207–1214.
17. Chan M, Liaw CS, Ji SM, Tan HH, Wong CY, Thike AA, 
Tan PH, Ho GH, Lee AS. Identification of circulating 
microRNA signatures for breast cancer detection. Clin 
Cancer Res. 2013; 19:4477–4487.
18. Heneghan HM, Miller N, Kelly R, Newell J, Kerin MJ. 
Systemic miRNA-195 differentiates breast cancer from 
other malignancies and is a potential biomarker for 
detecting noninvasive and early stage disease. Oncologist. 
2010; 15:673–682.
19. Madhavan D, Zucknick M, Wallwiener M, Cuk K, 
Modugno C, Scharpff M, Schott S, Heil J, Turchinovich A, 
Yang R, Benner A, Riethdorf S, Trumpp A, et al. Circulating 
miRNAs as surrogate markers for circulating tumor cells 
and prognostic markers in metastatic breast cancer. Clin 
Cancer Res. 2012; 18:5972–5982.
20. Schrauder MG, Strick R, Schulz-Wendtland R, Strissel PL, 
Kahmann L, Loehberg CR, Lux MP, Jud SM, Hartmann A, 
Hein A, Bayer CM, Bani MR, Richter S, et al. Circulating 
micro-RNAs as potential blood-based markers for early 
stage breast cancer detection. PLoS One. 2012; 7:e29770.
21. Li L, Guo Y, Chen Y, Wang J, Zhen L, Guo X, Liu J, Jing 
C. The Diagnostic Efficacy and Biological Effects of 
microRNA-29b for Colon Cancer. Technol Cancer Res 
Treat. 2016; 15:772–779.
22. Blondal T, Jensby Nielsen S, Baker A, Andreasen D, 
Mouritzen P, Wrang Teilum M, Dahlsveen IK. Assessing 
sample and miRNA profile quality in serum and plasma or 
other biofluids. Methods. 2013; 59:S1–6.
23. Sieuwerts AM, Kraan J, Bolt-de Vries J, van der Spoel P, 
Mostert B, Martens JW, Gratama JW, Sleijfer S, Foekens 
JA. Molecular characterization of circulating tumor 
cells in large quantities of contaminating leukocytes by a 
multiplex real-time PCR. Breast Cancer Res Treat. 2009; 
118:455–468.
24. Hochberg Y, Benjamini Y. More powerful procedures for 
multiple significance testing. Stat Med. 1990; 9:811–818.
25. Shimomura A, Shiino S, Kawauchi J, Takizawa S, 
Sakamoto H, Matsuzaki J, Ono M, Takeshita F, Niida S, 
Shimizu C, Fujiwara Y, Kinoshita T, Tamura K, et al. Novel 
combination of serum microRNA for detecting breast 
cancer in the early stage. Cancer Sci. 2016; 107:326–334.
26. McDermott AM, Miller N, Wall D, Martyn LM, Ball G, 
Sweeney KJ, Kerin MJ. Identification and validation of 
oncologic miRNA biomarkers for luminal A-like breast 
cancer. PLoS One. 2014; 9:e87032.
27. Cuk K, Zucknick M, Madhavan D, Schott S, Golatta 
M, Heil J, Marme F, Turchinovich A, Sinn P, Sohn C, 
Junkermann H, Schneeweiss A, Burwinkel B. Plasma 
microRNA panel for minimally invasive detection of breast 
cancer. PLoS One. 2013; 8:e76729.
28. Joosse SA, Muller V, Steinbach B, Pantel K, Schwarzenbach 
H. Circulating cell-free cancer-testis MAGE-A RNA, 
BORIS RNA, let-7b and miR-202 in the blood of patients 
with breast cancer and benign breast diseases. Br J Cancer. 
2014; 111:909–917.
29. Freres P, Wenric S, Boukerroucha M, Fasquelle C, Thiry 
J, Bovy N, Struman I, Geurts P, Collignon J, Schroeder 
H, Kridelka F, Lifrange E, Jossa V, et al. Circulating 
microRNA-based screening tool for breast cancer. 
Oncotarget. 2016; 7:5416–5428. https://doi.org/10.18632/
oncotarget.6786.
30. Wang G, Wang L, Sun S, Wu J, Wang Q. Quantitative 
measurement of serum microRNA-21 expression in relation 
to breast cancer metastasis in Chinese females. Ann Lab 
Med. 2015; 35:226–232.
31. Shaker O, Maher M, Nassar Y, Morcos G, Gad Z. Role 
of microRNAs -29b-2, -155, -197 and -205 as diagnostic 
Oncotarget24346www.oncotarget.com
biomarkers in serum of breast cancer females. Gene. 2015; 
560:77–82.
32. Erturk E, Cecener G, Egeli U, Tunca B, Tezcan G, Gokgoz 
S, Tolunay S, Tasdelen I. Expression status of let-7a and 
miR-335 among breast tumors in patients with and without 
germ-line BRCA mutations. Mol Cell Biochem. 2014; 
395:77–88.
33. Erturk E, Cecener G, Tezcan G, Egeli U, Tunca B, Gokgoz 
S, Tolunay S, Tasdelen I. BRCA mutations cause reduction 
in miR-200c expression in triple negative breast cancer. 
Gene. 2015; 556:163–169.
